ASSESSMENT OF THE QUALITY AND STABILITY OF THE COMBINED MEASLES–RUBELLA VACCINE MANUFACTURED AT POLYVAC, 2020–2026
DOI:
https://doi.org/10.56086/jcvb.v6i3.274Keywords:
MR vaccine, quality, thermostability, lot-to-lot consistencyAbstract
Background: The combined measles–rubella vaccine (MRVAC) manufactured by POLYVAC plays an important role in Vietnam’s Expanded Programme on Immunization. Quality control and stability evaluation in accordance with WHO Good Manufacturing Practices are essential to ensuring consistent vaccine quality and supporting safety and efficacy. Objective: To assess MRVAC quality and lot-to-lot consistency during 2020–2026 and the impact of bulk manufacturing process improvements on finished-product quality and stability. Methods: Quality control data from 49 finished-product lots were analyzed for potency, thermostability (37°C for seven days), physicochemical properties, sterility, and safety. Representative lots manufactured following process improvements underwent long-term stability testing at 2–8°C and accelerated stability testing at 25°C and 37°C. Pre-change and post-change data were compared statistically. Results: All lots met quality specifications. Mean measles potency was 4.40 ± 0.09 log₁₀ PFU/0.5 mL (CV, 2.07%), with a mean potency loss of 0.86 ± 0.07 log₁₀ after seven days at 37°C. Mean rubella potency was 3.81 ± 0.08 log₁₀ PFU/0.5 mL (CV, 1.99%), with a mean potency loss of 0.06 ± 0.03 log₁₀. Physicochemical and safety parameters met specifications, with minimal variability. Post-change lots showed long-term stability comparable to pre-change lots, meeting specifications through 24 months at 2–8°C, 90 days at 25°C, and 11 days at 37°C, with no abnormal quality trends observed. Conclusion: MRVAC manufactured during 2020–2026 demonstrated high lot-to-lot consistency, uniform quality, and robust thermostability. Manufacturing process improvements did not adversely affect product quality or stability.
